MARKET

ALKS

ALKS

Alkermes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.00
+0.18
+0.96%
After Hours: 19.00 0 0.00% 16:03 12/03 EST
OPEN
18.86
PREV CLOSE
18.82
HIGH
19.23
LOW
18.65
VOLUME
1.14M
TURNOVER
--
52 WEEK HIGH
21.86
52 WEEK LOW
11.98
MARKET CAP
3.02B
P/E (TTM)
-40.9042
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied to difficulties the agency has had in inspecting facilities where investigational drugs are being manufactured, amid COVID-19-related restrictions.
Benzinga · 5d ago
What Did Alkermes' (NASDAQ:ALKS) CEO Take Home Last Year?
Richard Pops has been the CEO of Alkermes plc (NASDAQ:ALKS) since 2011, and this article will examine the executive's...
Simply Wall St. · 11/24 04:35
Opioid Use Disorder Market to Soar at 10.8% CAGR and Hit USD 4.50 Billion by 2026; Increasing Research in Opioids by Pharmaceuticals to Aid Market Expansion: Fortune Business Insights(TM)
The global Opioid Use Disorder Market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period. Increasing addiction to opioids across the globe will be the central force driving the growth of this market, shares Fortune Business Insights(TM) in its recent report. The US National Institutes of Health (NIH) estimates that approximately 16 million people around the world are suffering from opioid use disorder (OUD).
GlobeNewswire · 11/23 12:14
The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates
Biotech stocks came under pressure in the week ended Nov. 20, reversing course from the previous week.
Benzinga · 11/22 12:22
Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS
Zacks · 11/18 17:24
Alkermes (ALKS) Receives FDA CRL in Relation to ALKS 3831
Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.
Zacks · 11/18 16:13
Alkermes, Inc. -- Moody's affirms Alkermes at Ba3; stable outlook
Moody's · 11/18 15:49
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16)
Benzinga · 11/17 13:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALKS. Analyze the recent business situations of Alkermes through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALKS stock price target is 19.45 with a high estimate of 24.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 321
Institutional Holdings: 162.72M
% Owned: 102.24%
Shares Outstanding: 159.15M
TypeInstitutionsShares
Increased
53
4.36M
New
45
5.47M
Decreased
55
11.70M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.07%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Pops
Chief Financial Officer/Senior Vice President
James Frates
Executive Vice President
Craig Hopkinson
Senior Vice President - Finance/Chief Accounting Officer
Iain Brown
Senior Vice President/Chief Compliance Officer/Secretary
David Gaffin
Senior Vice President/Chief Risk Officer
Michael Landine
Lead Director/Independent Director
David Anstice
Director
Shane Cooke
Independent Director
Robert Breyer
Independent Director
Wendy Dixon
Independent Director
Richard Gaynor
Independent Director
Paul Mitchell
Independent Director
Nancy Snyderman
Independent Director
Frank Wilson
Independent Director
Nancy Wysenski
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALKS
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alkermes Plc stock information, including NASDAQ:ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.